Recent content by neglect

At some point people matter more than the institution. I can think of several examples of amazing stroke programs: Cincinnati and Calgary that aren’t well known unless you’re in the field. So there is sometimes a disconnect. In the end it doesn’t matter for much as the qualities you bring.

The website explains a ton of it. Basically, these boards are monopoly, the only way to maintain certification is to pay them and do unnecessary work, although they want your money much more than your competence. So heroic doctors created an alternative board. This board only requires CME and...

The entire MOC thing is a scam. Use the alternative boards: NBPAS - Providing a Pathway for Continuous Certification

Let's beat up on the - checks notes - Alz Association for advocating for DMTs in Alzheimer's disease. It was written by two doofuses who also wrote "The Myth of Alzheimer's" which brings HIV denialism to Alzheimer's! Yeah, that's going to gain a lot of momentum. Powerful stuff. Thank you!

Met primary outcome. Met all secondary outcomes. Was even positive on caregiver QOL. At this point you're digging deeper into delusion. You going to finally tell us all how AChE-I slows progression?

Speech arrest with eye deviation to right is a gain in function left frontal lobe: seizure. Also stereotyped with second spell. The answer to this case is no longer TIA vs seizure, it is what anti-seizure med to use in a frail elderly man.

The question to you was very simple. How does AChE-I slow progression? Is your answer really going to be word choices used by Italians to describe Jody Cory Bloom's rivastigmine paper? Of course you don't have any COI. It is clear that you don't do work in this field. Equally obvious...

The data shows no significant difference between those who got ARIA and those who didn't. So your suspicion is unfounded, although subgroup analysis is a weak and limited look at the data. Your belief that acetylcholinesterase inhibitors "slowed decline" is false. These medications increase...

It includes a pure functional scale called the ADCS-ADL. But looking at the scales isn't as useful as looking at delays in progression. We now see that across all the mabs, we delay progression about 5-6 months over 18 months, so up to 1/2 a year over 1.5 years. See above. In aggregate...

Donanemab has positive results, published in Jama. All the haters were wrong. Reading the above like like opening a time capsule. https://jamanetwork.com/journals/jama/fullarticle/2807533

Full approval of lecanemab today with a reasonable black box warning for ARIA.

Many programs are inpatient heavy, so you'll have nearly zero exposure to movement, pain, dementia (aside from late stage folks in hospital), and limited exposure to peds. There's a HUGE difference between being a good neurologist and reading Stiff-Man, picking GAD AB's (an actual question that...

Lecanemab is 26,500 per year. To put that into context, bad first line MS drugs are at least 70K. Keytruda currently has accelerated approval for several indications (same as lec and adu) and is about 8X more expensive at 170K. Aliskiren is way outside my expertise. Cerebral edema due to...

On Friday the bottom line vote was 6-0 for full approval. Here's the discussion: June 9, 2023 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS)

The AAN's interests diverged from their member's interests LONG ago. With Sacco dead there's really no need to support them. Also, their conference sucks. It's just a big reunion. Med students and residents should still go.